Paragon Advisors LLC Makes New Investment in 10x Genomics (NYSE:TXG)

Paragon Advisors LLC bought a new position in 10x Genomics (NYSE:TXG) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 6,361 shares of the company’s stock, valued at approximately $568,000.

A number of other institutional investors also recently added to or reduced their stakes in TXG. Morgan Stanley boosted its holdings in 10x Genomics by 363.0% in the first quarter. Morgan Stanley now owns 5,048,578 shares of the company’s stock worth $314,628,000 after acquiring an additional 3,958,168 shares in the last quarter. SB Investment Advisers UK Ltd. bought a new stake in 10x Genomics in the first quarter worth $239,074,000. Invesco Ltd. boosted its holdings in 10x Genomics by 170.3% in the first quarter. Invesco Ltd. now owns 1,255,022 shares of the company’s stock worth $78,213,000 after acquiring an additional 790,769 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in 10x Genomics by 227.4% in the fourth quarter. Alliancebernstein L.P. now owns 978,317 shares of the company’s stock worth $74,597,000 after acquiring an additional 679,482 shares in the last quarter. Finally, VR Adviser LLC bought a new position in shares of 10x Genomics during the first quarter valued at $18,696,000.

10x Genomics stock traded down $1.18 during mid-day trading on Tuesday, reaching $88.96. 11,383 shares of the stock traded hands, compared to its average volume of 660,647. 10x Genomics has a 12-month low of $45.11 and a 12-month high of $108.36. The business’s 50-day moving average is $83.03 and its 200-day moving average is $77.98.

10x Genomics (NYSE:TXG) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.09). The company had revenue of $71.91 million during the quarter, compared to the consensus estimate of $71.67 million. The business’s revenue was up 34.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.25) EPS.

A number of research analysts have recently issued reports on TXG shares. Citigroup upped their price target on 10x Genomics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Zacks Investment Research downgraded 10x Genomics from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Cowen upped their price target on 10x Genomics from $68.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. upped their price target on 10x Genomics from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. 10x Genomics presently has a consensus rating of “Buy” and a consensus price target of $84.00.

In other 10x Genomics news, Director Bryan E. Roberts sold 3,100,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $78.00, for a total value of $241,800,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John R. Stuelpnagel sold 7,500 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $89.14, for a total value of $668,550.00. Following the completion of the sale, the director now owns 582,196 shares of the company’s stock, valued at approximately $51,896,951.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,709,819 shares of company stock valued at $449,083,195.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems.

See Also: Quantitative Easing

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NYSE:TXG).

Institutional Ownership by Quarter for 10x Genomics (NYSE:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.